Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study

Jeffrey A. Allen, Mamatha Pasnoor, Mazen M. Dimachkie, Senda Ajroud-Driss, Thomas H. Brannagan, Albert A. Cook, Timothy Walton, Mark B. Fiecas, John T. Kissel, Ingemar Merkies, Kenneth C. Gorson, Richard A. Lewis

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Objective The objective of this study was to explore the extent of IV immunoglobulin (IVIG) treatment-related fluctuations (TRFs) by using home collection of daily grip strength in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and to use that information to develop evidence-based treatment optimization strategies.MethodsThis prospective observational study included 25 patients with well-defined CIDP. Participants recorded grip strength daily for 6 months. Disability and gait metrics were collected weekly. Serum immunoglobulin G levels were obtained at peak, trough, and midcycle IVIG intervals. Day-to-day grip strength changes <10% were considered random. To identify patients with TRFs, 3-day averaged grip strength was calculated on each consecutive day after an IVIG infusion. TRFs were defined as ≥10% 3-day averaged grip strength difference compared to the pre-IVIG baseline.ResultsParticipants successfully recorded grip strength on all but 9% of recordable days. Twelve patients (48%) were classified as low/no fluctuaters and 13 (52%) as frequent fluctuaters. In the frequent fluctuating group, grip strength improved over 1 week and thereafter was relatively stable until the third week after infusion. Grip strength was significantly correlated with measures of disability.ConclusionsGrip strength collection by patients at home is reliable, valid, and feasible. A change in grip strength by ≥10% is a useful, practical, and evidence-based approach that may be used to identify clinically meaningful TRFs. From these data, we propose a treatment optimization strategy for patients with CIDP on chronic IVIG that may be applied to routine clinic care during both face-to-face and virtual video or telephone patient encounters.Trial Registration InformationClinicalTrials.gov Identifier: NCT02414490.

Original languageEnglish (US)
Pages (from-to)E1876-E1886
JournalNeurology
Volume96
Issue number14
DOIs
StatePublished - Apr 6 2021

Bibliographical note

Publisher Copyright:
© American Academy of Neurology.

Keywords

  • Adult
  • Aged
  • Disability Evaluation
  • Female
  • Hand Strength
  • Humans
  • Immunoglobulins, Intravenous/therapeutic use
  • Male
  • Middle Aged
  • Patient Reported Outcome Measures
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/drug therapy
  • Recovery of Function
  • Young Adult

PubMed: MeSH publication types

  • Research Support, Non-U.S. Gov't
  • Observational Study
  • Journal Article

Fingerprint

Dive into the research topics of 'Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study'. Together they form a unique fingerprint.

Cite this